NASDAQ:CLDX Celldex Therapeutics Q3 2025 Earnings Results & Report $28.25 -1.18 (-4.01%) Closing price 04:00 PM EasternExtended Trading$28.25 0.00 (0.00%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Celldex Therapeutics missed analyst earnings expectations in its Q3 2025 results, released November 10, 2025. The company reported EPS of -$1.01 versus the -$0.88 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2025Report DateNovember 10, 2025TimeBefore Market OpensConference Call12:00 AM ET Celldex Therapeutics EPS ResultsActual EPS-$1.01Consensus EPS -$0.88Beat/MissMissed by -$0.13One Year Ago EPSN/AEPS Beat Rate4 of last 8 quartersCelldex Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$1.12 millionBeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsCelldex Therapeutics' Q3 2026 earnings is estimated for Monday, November 9, 2026, based on past reporting schedules, with a conference call scheduled on Monday, November 2, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K)Quarterly Report(10-Q) Celldex Therapeutics Q3 2025 Earnings FAQ Did Celldex Therapeutics beat earnings estimates for Q3 2025? Celldex Therapeutics (NASDAQ:CLDX) reported earnings of -$1.01 per share for Q3 2025, missing the consensus estimate of -$0.88. The report was announced on Monday, November 10, 2025. When is Celldex Therapeutics' next earnings date? Celldex Therapeutics' next earnings date is estimated for Monday, November 9, 2026. MarketBeat tracks confirmed and estimated earnings dates for Celldex Therapeutics on the company's earnings history page. Celldex Therapeutics Earnings HeadlinesSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Celldex Therapeutics, Inc. (NASDAQ: CLDX)October 12 at 9:10 AM | prnewswire.comCelldex Therapeutics, Inc. (NASDAQ:CLDX) Stock Has Consensus Price Target of $61.92October 9, 2026 | americanbankingnews.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.October 13 at 1:00 AM | Porter & Company (Ad)Celldex Therapeutics: Trying To Put Its Troubled History Behind ItOctober 7, 2026 | seekingalpha.comCelldex Therapeutics (NASDAQ:CLDX) vs. Senti Biosciences (NASDAQ:SNTI) Critical SurveyOctober 7, 2026 | americanbankingnews.comCelldex (CLDX) Receives a Rating Update from a Top AnalystOctober 4, 2026 | theglobeandmail.comSee More Celldex Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Celldex Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Celldex Therapeutics and other key companies, straight to your email. Email Address About Celldex TherapeuticsCelldex Therapeutics (NASDAQ:CLDX) is a clinical-stage biopharmaceutical company focused on developing antibody-based therapies for diseases with significant unmet medical needs. The company’s research programs target mast cell–mediated disorders, inflammatory diseases, and cancer, using engineered antibodies designed to modulate specific immune-system pathways. Celldex’s lead product candidate is barzolvolimab, an investigational monoclonal antibody that targets the KIT receptor on mast cells. The company is evaluating barzolvolimab in conditions including chronic spontaneous urticaria and prurigo nodularis. Celldex also maintains an oncology and immunology pipeline that includes investigational antibody programs designed to stimulate or regulate immune responses. Founded in the United States, Celldex conducts research and clinical development activities through collaborations and clinical studies in the U.S. and other international markets. The company is headquartered in Hampton, New Jersey, and is led by Anthony S. Marucci, who serves as president and chief executive officer.View Celldex Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Surgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow RunwayJPMorgan Earnings Miss Estimates But Reveal Broad-Based StrengthAmazon's $220 Billion AI Bet Is Getting Bigger—Can Earnings Justify the Spending?A Silent Winner: Texas Instruments Anchors the AI SupercycleDelta's Guidance Cut Could Spell Trouble for the Airline Industry5 Retail Picks to Watch as the Holiday Shopping Season Nears Upcoming Earnings Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026)Fastenal (10/14/2026)ASML (10/14/2026)Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
